ENDLOS-TURBO PUT - GILEAD SCIENCES | Delayed Deutsche Boerse AG 08:35:18 2024-07-02 EDT | ||
| 3.76 EUR | +0.80% |
|
| Current month | -1.32% | ||
| 1 month | -10.55% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-02 | 3.76 | +0.80% |
| 24-07-01 | 3.73 | -1.32% |
| 24-06-28 | 3.78 | +1.89% |
| 24-06-27 | 3.71 | +0.82% |
| 24-06-26 | 3.68 | +1.38% |
Delayed Quote Deutsche Boerse AG
Last update July 02, 2024 at 08:35 am
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | DZ BANK |
| WKN | DW63US |
| ISIN | DE000DW63US1 |
| Date issued | 2022-11-01 |
| Strike | 108.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.21 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.36 € |
|---|---|
| Lowest since issue | 1.92 € |
| Spread | 0.02 € |
| Spread % | 0.53% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
68.64
USD
Average target price
82.97
USD
Spread / Average Target
+20.87%
- Stock Market
- Certificates
- Certificat
